COVID-19 Vaccine Frequently Asked Questions – Vaccine Providers

Answers to common questions from vaccine providers about the COVID-19 vaccine.

This FAQ covers administrative considerations, vaccine administration, prioritization, safety, storage, and MIIS registration, enrollment, and training. It will be updated regularly as new questions arise. Please also refer to Guidance on COVID-19 vaccine management and administration for healthcare providers & organizations for additional clinical and technical information.

Table of Contents

Administrative considerations

Is there a cost to providers to receive and administer the vaccine?  

There is no cost for the vaccine or ancillary kits. The U.S. Centers for Medicare and Medicaid Services (CMS) has approved reimbursement for the administration of the vaccine. While vaccine providers may not bill for the COVID-19 vaccine itself, many vaccine providers in the state have contracted with outside entities, such as Commonwealth Medicine, to assist with insurance billing for the costs of administering the vaccine.  The Department is not a party to these agreements, but if your site has such an agreement you may wish to familiarize yourself with its terms.  

Does the Massachusetts COVID-19 Vaccine Program provide up-front funding to administer COVID-19 vaccine?  

At this time, there is no up-front funding for administration-related costs through the federal government or from the state. Vaccine and some related supplies (syringes, needles) are being supplied by the federal government. Providers may bill Medicare, Medicaid, and private insurers for the cost of administering COVID-19 vaccine. For more information, please see COVID-19 Vaccine Coverage and Reimbursement Update from the Massachusetts Medical Society.  

Does FEMA provide funding to cover vaccination costs?

Yes, eligible Applicants under the FEMA Public Assistance (PA) Program may seek 100% reimbursement for uncovered vaccination costs.  Eligible Applicants include state, local, and tribal governments along with not-for-profit healthcare providers, Boards of Health, and other quasi-governmental agencies.  The PA Program is administered through the Massachusetts Emergency Management Agency (MEMA).  For more information you can visit MEMA’s website, or email your questions to disaster.recovery@mass.gov

Is there a cost to vaccine recipients?

Providers must administer COVID-19 Vaccine regardless of the vaccine recipient’s ability to pay administration fees or the recipient’s insurance coverage status. Providers may seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the vaccine recipient. Providers may not seek co-payment, reimbursement or any form of cost sharing, including through balance billing, from the vaccine recipient.

Is the COVID-19 vaccine mandated by DPH?

No, the COVID-19 vaccine is not mandated by DPH. It is a voluntary vaccination program. The COVID-19 vaccine has been shown to be highly effective at preventing illness and even more effective at preventing severe disease leading to hospitalization or death; it is the single best tool in the fight against the pandemic.​

Is consent needed for COVID-19 vaccination?

Obtaining informed consent is a vital part of the vaccine administration process. Vaccine providers should consult with their legal counsel regarding an appropriate informed consent process and what documentation may be recommended or required by their particular organization. Information regarding informed consent for minors is provided below. 

What procedure should a vaccine provider follow to obtain consent to administer a COVID-19 vaccine to someone who is under 18?

It is the responsibility of vaccine providers to obtain appropriate consent from patients before administering a vaccination. The expectation is that every vaccine provider in the Commonwealth will establish appropriate procedures which minimize hurdles to vaccination for minors, and make those requirements, including any required forms, easy to understand and accessible.

For minors, consent is obtained from a legally authorized representative on behalf of the child (usually a parent or guardian).  The legally authorized representative does not need to accompany the minor to the vaccination appointment in order to provide consent for a vaccination.  Vaccine providers are strongly encouraged to request written consent from the appropriate legally authorized representative, such as a written consent form, that the minor may then bring to their vaccine appointment.  A model consent form is available here for providers to utilize for this purpose.

What information do we need to provide vaccine recipients about the COVID-19 vaccines?

All people age 5 years and older are recommended to receive an age-appropriate COVID-19 vaccination. 

In most situations, Pfizer-BioNTech or Moderna COVID-19 Vaccines are preferred over the Janssen COVID-19 Vaccine for primary and booster vaccination.

A booster dose of COVID-19 vaccine is recommended for everyone ages 12 years and older. Timing of a booster dose varies based on COVID-19 vaccine product and immunocompetence.

Answers to many questions can be found at:

Depending on the situation, you will need to provide either an EUA Fact Sheet for Recipients and Caregivers, or a EUI Factsheet for Recipients and Caregivers.

Currently, there is no Vaccine Information Sheet (VIS) for COVID-19 vaccines authorized under an EUA. For each COVID-19 vaccine authorized under an EUA, the FDA requires that vaccine recipients or their caregivers are provided with certain vaccine-specific EUA information to help make an informed decision about vaccination. This is accomplished by providing an EUA Fact Sheet for Recipients and Caregivers. The Fact Sheet is similar in purpose and content to VISs for licensed vaccines but differs in that the EUA Fact Sheet is specific to each authorized COVID-19 vaccine, is developed by the manufacturer of the vaccine, and is authorized by the FDA. There is a separate EUA Fact Sheet for each formulation of a vaccine. For example, there are different Fact Sheets for each of the three Pfizer-BioNTech COVID-19 Vaccine formulations (orange cap, gray cap, and purple cap).

CDC has also issued Emergency Use Instructions (EUI) for use of the COVID-19 vaccine by Pfizer-BioNTech and COVID-19 vaccine by Moderna for primary, additional, and/or booster doses in certain individuals. The EUI are necessary because these uses extend beyond their FDA-approved labeling. The EUI and CDC’s clinical guidance help to ensure these individuals can get primary, additional, and/or booster doses of the COVID-19 vaccine by Pfizer-BioNTech or Moderna so they can be better protected against COVID-19. The EUI are currently issued only for Pfizer-BioNTech and Moderna COVID-19 vaccines since EUI can only apply to FDA-approved medical products. People vaccinated in accordance with these emergency use instructions should be given an EUI Fact Sheet at the time of vaccination. 

EUA Factsheets can be found here: 

Once a new EUA Fact Sheet is issued, it must be used. Previous ones no longer contain accurate information.

View EUI Fact Sheets | CDC.

Do we need a standing order for COVID-19 vaccine clinics?

Yes, you need to obtain a standing order for your program from a medical professional, such as a physician. 

What liability protections do COVID-19 vaccinators have?  

People or entities with liability or other legal questions should consult with their legal counsel. You and your legal counsel may wish to review the federal Public Readiness and Emergency Preparedness Act (PREP Act) and/or the Massachusetts Act to Provide Liability Protections for Health Care Workers and Facilities During the COVID-19 Pandemic.

Can healthcare providers submit claims for uninsured individuals who are undocumented?

Health care providers are not required to confirm immigration status prior to submitting claims for reimbursement. Health care providers who have conducted COVID-19 testing of any uninsured individual, provided treatment to any uninsured individual with a COVID-19 primary diagnosis, or administered a licensed or authorized COVID-19 vaccine to an uninsured individual for dates of service or admittance on or after February 4, 2020, may be eligible for claims reimbursement through the program as long as the service(s) provided meet the coverage and billing requirements established as part of the program. (source: FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration, hrsa.gov)

Can people who live in Massachusetts but work in another state receive vaccine in Massachusetts? How about those who work in Massachusetts but live in another state?  

Yes. The Massachusetts COVID-19 Vaccination program is intended for individuals who live, work or study in the state.

Vaccine administration

Who can administer vaccine?

This COVID-19 Vaccinators chart lists the different groups of individuals who can possess and administer COVID-19 vaccines.

Is training required for providers to be able to administer the vaccine?

DPH strongly encourages the primary and back-up vaccine coordinators at each site and providers administering COVID-19 vaccine to complete the trainings in vaccine storage and handling and administration found at Massachusetts COVID-19 Vaccine Program (MCVP) Overview | Mass.gov.

How will patients know which vaccine they receive and, if applicable, when they need the second dose?

The vaccine ancillary supply kits will come with vaccine record cards that can be given to the patients indicating what vaccine they received and, if applicable, that they need a second dose.  Vaccine record cards may be reproduced, if necessary. In addition, there will be electronic reminder/recall systems in the MIIS that providers could use in addition to their own EHR systems to send reminders to patients about their second dose. More information about the v-safe app, which also includes a patient reminder recall, can be found at V-safe After Vaccination Health Checker | CDC. Providers should schedule the 2nd dose at the time the 1st dose is administered.

What should a site do if a vaccine recipient has lost or misplaced their COVID-19 Vaccination Record Card?

Vaccine recipients should be encouraged to obtain a record of their immunization record directly from the administering provider or site.

Administering providers and vaccination sites can create a new record card for the recipient. They can order blank COVID-19 Vaccination Record Cards in English and Spanish from the Massachusetts Clearing House at no cost and use the recipient’s vaccine records (either the electronic health record or MIIS) to fill out a replacement card.  

If a provider or site does not have access to the patient’s electronic health record, they may access the patient’s immunization record in the MIIS. This Mini Guide provides step-by-step instructions for providers to access and print a patient’s immunization record in the MIIS. Please note that the MIIS cannot provide patients with COVID-19 Vaccination Record Cards.

Providers and vaccination sites can also advise vaccine recipients on the following options:

  1. They may be able to print their electronic health record directly from their provider’s health care portal.
  2. They can access their record in v-safe, if they enrolled in the program.  

When is the 2nd dose due for Pfizer and Moderna?

Both the Pfizer and Moderna COVID-19 vaccine require 2 doses.

  • Pfizer-BioNTech (30 µg, 0.3 ml each): at least three weeks (21 days) apart
  • Moderna (100 µg, 0.5 ml): at least one month (28 days) apart

CDC updated recommendations on February 22, 2022, summarized as follows:

  • An 8-week interval between the first and second doses of a primary mRNA vaccine schedule may be optimal for some people age 12 years or older, especially males age 12 through 39 years at the highest risk of myocarditis following dose 2. Compared to shorter intervals, an 8-week interval produced higher antibody levels and was associated with a lower risk of myocarditis following the second dose.
  • The original 3- or 4-week intervals remain the recommended intervals for people who need to be protected from COVID-19 more quickly, including those who are moderately or severely immunocompromised, adults 65 years or older, children under 12, and others who need rapid protection related to community transmission or risk of severe disease.

Learn more: Updated_ICC-intervals-2-22-22.pdf

On March 29, CDC updated its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19.  Please note: the tables below have not yet been updated to reflect the new guidance.

COVID-19 vaccination schedule for the primary series in the general population*

Primary series vaccine manufacturer Age group Number of doses in primary series Number of booster doses Interval between 1st and 2nd dose Interval between primary series and booster dose
Pfizer-BioNTech 5–11 years 2 NA 3 weeks NA
Pfizer-BioNTech ≥12 years 2 1 3-8 weeks ≥5 months
Moderna ≥18 years 2 1 4-8 weeks ≥5 months
Janssen ≥18 years 1 1 NA ≥2 months

*For the vaccination schedule for people who are moderately or severely immunocompromised, see CDC’s Table 3

An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years.  A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for: people who are moderately to severely immunocompromised; adults ages 65 years and older; and others who need rapid protection due to increased concern about community transmission or risk of severe disease.

Pfizer-BioNTech COVID-19 Vaccine is FDA-approved or FDA-authorized in people ages 5 years and older as a 2-dose primary series, with an interval of 3 weeks between doses.

Vaccination providers should ensure the correct age-appropriate formulation is administered based on the recipient’s age on the day of vaccination (Table 1).

Moderna COVID-19 Vaccine is FDA-approved or FDA-authorized in people ages 18 years and older as a 2-dose primary series, with an interval of 4 weeks between doses.

For mRNA vaccine series, the same mRNA vaccine product should be used for all doses of the primary series (for more info see CDC’s Interchangeability of COVID-19 vaccine products).

4-Day Grace Period

Doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered valid. If a dose is administered prior to the 4-day grace period and is a:

  • Primary series dose, it should be repeated; the repeat dose should be spaced from the date of the dose given in error by the recommended minimum interval.
  • Booster dose; it should not be repeated.

Doses administered at any time after the recommended interval are valid.

Recommendations may be updated as further information becomes available or additional vaccine types authorized.

Who is eligible to get a booster dose?

Massachusetts residents age 12 and over may get a COVID-19 booster if it has been at least 5 months since their second dose of the Pfizer or Moderna vaccine or 2 months since their J&J/Janssen single dose vaccine. Individuals with moderate to severe immunocompromise who received a third mRNA COVID-19 vaccine as part of their primary series are eligible for a booster dose 3 months after their third dose.

Who is eligible to get a second booster dose?

Following FDA’s regulatory action on March 29, CDC updated its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19.

Separately and in addition, based on newly published data, adults who received a primary vaccine and booster dose of Johnson & Johnson’s Janssen COVID-19 vaccine at least 4 months ago may now receive a second booster dose using an mRNA COVID-19 vaccine.

These updated recommendations acknowledge the increased risk of severe disease in certain populations including those who are elderly or over the age of 50 with multiple underlying conditions, along with the currently available data on vaccine and booster effectiveness.

  • A 2nd booster dose of the Pfizer or Moderna may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
  • A 2nd booster dose of the Pfizer may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
  • A 2nd booster dose of the Moderna may be administered to individuals 18 years of age and older with the same certain kinds of immunocompromise at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine

What are the COVID-19 vaccine formulations currently approved or authorized for primary series and boosters?

On March 29, CDC updated its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19.

Please note: the tables below have not yet been updated to reflect the new guidance.

Vaccine manufacturer Age indication Vaccine vial cap color Dilution required Primary series dose Primary series injection volume Booster dose Booster dose injection volume
Pfizer-BioNTech 5–11 years Orange Yes 10 µg 0.2 mL NA NA
Pfizer-BioNTech ≥12 years Purple Yes 30 µg 0.3 mL 30 µg 0.3 mL
Pfizer-BioNTech ≥12 years Gray No 30 µg 0.3 mL 30 µg 0.3 mL
Moderna ≥18 years NA No 100 µg 0.5 mL 50 µg 0.25 mL
Janssen ≥18 years NA No 5×1010 viral particles 0.5 mL 5×1010 viral particles 0.5 mL

COVID-19 vaccine booster, after a mRNA primary series (Pfizer or Moderna)

All people ages 12 years and older should receive an age-appropriate booster dose and formulation of COVID-19 vaccine, even if they were age 11 years or younger at the time of the primary series. Currently, COVID-19 vaccines are not authorized for a booster dose for children ages 11 years and younger.

The recommended interval for the booster dose is based on the product received for the primary series. In most people, the interval is:

  • At least 5 months after mRNA 2-dose primary vaccination or
  • At least 2 months after Janssen single dose primary vaccination

Following FDA’s regulatory action on March 29, CDC updated its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19.

For information about schedules and booster doses for people who are moderately or severely immunocompromised, see guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised.

Individuals 12-17 years old may only receive Pfizer-BioNTech for both their primary series and booster doses. For individuals 18 and older, any FDA-approved or authorized COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) can be used as the booster dose. The mRNA vaccines (Pfizer-BioNTech or Moderna) are preferred over J&J/Janssen for both the primary series and booster dose.

COVID-19 vaccine booster, after a J&J/Janssen primary series

Anyone age 18 or older may receive a booster shot at least 2 months after their J&J/Janssen vaccine.

Any FDA-approved or authorized COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) can be used as the booster dose, at an interval of at least 2 months since the primary Janssen vaccine dose. The mRNA vaccines (Pfizer-BioNTech or Moderna) are now preferred over J&J/Janssen for both the primary series and booster dose.

For information about schedules and booster doses for people who are moderately or severely immunocompromised, see guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised.

Patients with moderate to severe immunocompromise

People with immunocompromising conditions or people who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Because the immune response following COVID-19 vaccination may differ in moderately or severely immunocompromised people, specific guidance for this population is provided. Use of mRNA vaccines is preferred.

On March 29 CDC updated its recommendations to allow certain immunocompromised individuals who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19.

  • A 2nd booster dose of the Pfizer may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
  • A 2nd booster dose of the Moderna may be administered to individuals 18 years of age and older with the same certain kinds of immunocompromise at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine
Guidance for People who are Moderately or Severely Immunocompromised and Vaccinated with Janssen COVID-19 Vaccine

There is detailed guidance in Appendix D of the Clinical Considerations.

Mixing vaccines

Current guidelines recommend that the primary series, including a possible third dose for moderate to severe immunocompromise, be with the same vaccine product.

For a booster dose, any FDA-approved or authorized COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) can be used, regardless of vaccine received for primary series. The mRNA vaccines (Pfizer-BioNTech or Moderna) are now preferred over J&J/Janssen for both the primary series and booster dose.

The timing of the booster dose is based on the recipient’s primary series product, regardless of the product used for the booster dose.

Examples:
  • If I got my second Moderna shot at least 5 months ago and I meet the eligibility criteria, I can get Moderna or Pfizer now
  • If I got my Janssen vaccine 2 months ago, and I meet the eligibility criteria, I can get Moderna or Pfizer now
  • If I got my second Pfizer shot at least 5 months ago, and I meet the eligibility criteria, I can get Moderna or Pfizer now
  • If I got a third dose of Pfizer or Moderna because of severe immunocompromise at least 5 months ago, and I meet the eligibility criteria, I can get Moderna or Pfizer or now
  • If I got final primary series shot of Pfizer or Moderna 3 months ago, I can NOT yet get a booster dose. It needs to be at least 5 months since my final dose before I do.
More information:

What role should long-term care/skilled nursing and correctional facilities play in ensuring access to second doses for individuals who leave their facilities?  

Anyone receiving their first dose of vaccine in a LTCF/SNF or correctional facility is eligible for a second dose after they leave. LTCF/SNFs and correctional facilities should make every effort to support individuals to plan for their second dose before they leave the facility. This can include making an appointment at a publicly available clinic (see vaxfinder.mass.gov) or directing the individual to other options the facility manages. Individuals should always be given a vaccination card indicating the manufacturer, lot, date administered, and the date the second dose is due. It is best practice that the administrator of the first dose actively supports individuals to receive the second, even if they cannot administer it directly.

What should a site do with extra vaccine?  

Vaccine can be transferred to sites that have completed an MCVP Agreement. Please note that this does not apply to temporary off-site clinics. Such a transfer must be done in consultation with the Vaccine Unit. Visit Massachusetts COVID-19 Vaccine Program (MCVP) – Guidance for Vaccine Providers and Organizations | Mass.gov for more guidance on redistribution.

What should we do with unused doses of COVID-19 vaccine in a multi-dose vial?

Vaccinators should withdraw only the authorized number of doses from each vial of COVID-19 vaccine.  The number of authorized doses is indicated on the vaccine packaging in the provider EUA fact sheet for each vaccine.  The actual number of doses that a vaccinator can get from each vial may be affected by the type of needle and syringe used. If less than the number of authorized doses is used by the Beyond Use Date (BUD), the vial and remaining vaccine must be discarded in a sharps container.  With Pfizer and Janssen (J&J) vaccine, any doses not used must be reported as wasted.  For Moderna vaccine, an unextracted 15th dose in a maximum-15 dose vial does not count as waste.

What is our obligation to follow the Emergency Use Authorization (EUA) terms and principles of non-discrimination in administration?

Providers must follow the EUA.  Decisions about which eligible patients receive the COVID Vaccine should be based on the clinical judgment of hospitals and providers, consistent with the terms of the EUAs and with this guidance. Provider criteria for the COVID Vaccine use should be as clear, transparent, and objective as possible, and be based on biological factors related only to the likelihood and magnitude of benefit from the medical resources and should at all times minimize inequitable outcomes. Factors that have no bearing on the likelihood or magnitude of immunization benefit, include but are not limited to, race, disability, gender, sexual orientation, gender identity, ethnicity, ability to pay or insurance status, socioeconomic status, English language proficiency, perceived social worth, perceived quality of life, immigration status, incarceration status, homelessness, or past or future use of resources.

What happens if a vaccine recipient does not receive a full dose or the dose is given subcutaneously (SC), not intramuscularly (IM)?   

  • If a lower-than-authorized dose volume was administered (e.g., leaked out, equipment failure, recipient pulled away):
    • If more than half of the dose was administered do not repeat the dose.
    • If less than half of the dose was administered or the proportion of the dose cannot be estimated, administer the authorized dose immediately (no minimum interval) in the opposite arm.  If the dose given in error is the first dose of a two-dose series, the second dose should be administered at the recommended interval (21 days [Pfizer-BioNTech] or 28 days [Moderna]) from the date of receipt of the valid dose (not the date of receipt of the erroneous dose).  
  • If a dose is given by an incorrect route, e.g., subcutaneously, do not repeat dose.  Inform the recipient of the potential for local and systemic adverse events. 
  • Report all COVID-19 vaccination errors to VAERS.hhs.gov.

Will a person test positive for COVID-19 after getting the vaccine? 

None of the recently authorized and recommended vaccines nor the other COVID-19 vaccines currently in clinical trials in the United States can cause you to test positive on viral tests, which are used to see if you have a current infection.​ Viral tests (molecular [e.g., PCR] or antigen) to detect current infection will still be accurate if you have been vaccinated.

If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests. Antibody tests look for evidence of a previous infection and that you may have some level of immunity to the virus. Experts are currently looking at how COVID-19 vaccination may affect antibody testing results.

Vaccine safety

Should someone who is COVID-19-positive receive the vaccine?

Vaccination of persons with known current SARS-CoV-2 infection should be deferred until their isolation period has ended, usually 10 days after their symptoms began or their test was positive (if asymptomatic) While there is otherwise no recommended minimum interval between infection and vaccination, current evidence suggests that reinfection is uncommon in the 90 days after initial infection.

Is it safe for people to get a COVID-19 vaccine if they would like to have a baby one day?

Yes. People who want to get pregnant in the future may receive any of the COVID-19 vaccines. Based on current knowledge, experts believe that COVID-19 vaccines are very unlikely to pose a risk to a person trying to become pregnant in the short or long term. Scientists study every vaccine carefully for side effects immediately and for years afterward.  The COVID-19 vaccines are being studied carefully now and will continue to be studied for many years, similar to other vaccines.

The COVID-19 vaccine, like other vaccines, works by training our bodies to develop antibodies to fight against the virus that causes COVID-19, to prevent future illness. There is currently no evidence that antibodies formed from COVID-19 vaccination cause any problems with pregnancy, including the development of the placenta. In addition, there is no evidence suggesting that fertility problems are a side effect of ANY vaccine. People who are trying to become pregnant now or who plan to try in the future may receive the COVID-19 vaccine when it becomes available to them.

Can the COVID-19 vaccines be given to people who are pregnant?

  • Yes. Any of the currently authorized COVID-19 vaccines can be administered to pregnant or lactating people; ACIP does not state a product preference.
  • There are limited data on the safety of COVID-19 vaccines in people who are pregnant. Early data from v-safe and VAERS did not identify any safety concerns for pregnant people who were vaccinated or for their babies.  There were no vaccine-related adverse events reported on female fertility, fetal development or postnatal development from animal studies with all 3 vaccines.
  • COVID-19 infection during pregnancy can result in an increased risk of severe illness (ICU admission, mechanical ventilation and death) and might result in an increased risk of adverse pregnancy outcomes, such as preterm birth.
  • Consider the following when discussing COVID-19 vaccination with people who are pregnant:
    • Level of COVID-19 community transmission (risk of acquisition)
    • Personal risk of contracting COVID-19  
    • The risks of COVID-19 to the person who is pregnant and potential risks to the fetus
    • The efficacy of the vaccine
    • The known side effects of the vaccine
    • The limited but growing data about the vaccine during pregnancy
  • Pregnant people who experience fever following vaccination should be counseled to take acetaminophen as fever has been associated with adverse pregnancy outcomes.
  • Routine testing for pregnancy prior to receipt of a COVID-19 vaccine is not recommended.
  • For more information, visit Interim Clinical Considerations for Use of COVID-19 Vaccines.

How can we balance potential side effects of the vaccine with healthcare providers needing to be available to work?

Systemic signs and symptoms, such as fever, fatigue, headache, chills, myalgia, and arthralgia, can occur following COVID-19 vaccination. Preliminary data from COVID-19 vaccine trials indicate that most systemic post-vaccination signs and symptoms are mild to moderate in severity, occur within the first three days of vaccination (the day of vaccination and following two days, with most occurring the day after vaccination), resolve within 1-2 days of onset, and are more frequent and severe following the second dose and among younger persons compared to those who are older (>55 years). Cough, shortness of breath, rhinorrhea, sore throat, or loss of taste or smell are not consistent with post-vaccination symptoms, and instead may be symptoms of COVID-19 or another infection.

DPH guidance about Considerations for Health Care Personnel After COVID-19 Vaccination can be found here.

Vaccine storage

If we obtain capacity for storing at ultra-cold temperatures after we have submitted information to MIIS that we did not have capacity, what is the best way to update the system?

If there is any change in your storage capacity, please email the DPH Vaccine Unit at dph-vaccine-management@massmail.state.ma.us to update your information.

We are planning as a system and exploring central storage for our entities. How should we fill out the DPH and CDC forms regarding capacity within each type of storage (i.e. ultra-cold)? Will it be possible for us to receive all at one storage location?

You must enroll each location and note “ultra-cold” storage capacity at each location. DPH can work with you to have all of your site’s supply forwarded to the central ultra-cold storage location.

Should vaccination sites have security for vaccine inventory?  

Vaccination sites are responsible for maintaining vaccine inventory delivered to the site secure. However, armed security guards or special security details are not required.

What credentials are required of individuals responsible for receiving vaccine shipment, managing inventory, and serving as vaccine coordinators and backup coordinators?

No credentials are required, but the individual must participate in required trainings (see question 32). The vaccine coordinator and back-up coordinator should be employees or contractors of the entity that is enrolled in the MCVP and receiving the vaccine.

Are the refrigerators and freezers required to be pharmacy grade?

Pharmaceutical and purpose-built refrigerators are a vaccine storage and handling best practice but are not required for the storage of COVID-19 vaccine. Standalone freezers are strongly recommended, as the freezer portion of a household combination unit may not reliably maintain temperatures. If that is not possible for your site, please contact the Vaccine Unit at DPH-Vaccine-Management@massmail.state.ma.us for further guidance to ensure maintenance of appropriate temperatures. All storage units must be monitored continuously. The best practice for monitoring temperatures is to use a digital data logger available from DPH.

MIIS registration, enrollment, and training

Should we ask our sites to update their information stored in MIIS Vaccines module to be that of our central depot or will this be something we can address separately? 

No, please do not ask sites to update their vaccine information in the vaccine module as that will result in all routine vaccines now being shipped to the new location. We will develop a separate mechanism to capture the necessary information we need for hospital networks that will be using a central depot model.

Can the MIIS be used for pulling patient lists for defined prioritization based on age and higher risk diagnoses, for ease of outreach?

Providers can use the MIIS to run two reports that list patients by age - the Practice Population Report and the Patients Vaccinated Report. The Practice Population Report allows you to enter an age range. You can sort by birthdate on the report output. On the Patients Vaccinated Report you can also enter an age range, or leave it blank to run it by administration date or by vaccines the patients have received, and then sort by birthdate on the output.

My site administers immunizations directly. Am I required to register with and report data to the MIIS?

Yes. Reporting of immunization data to the MIIS is required by state law for all MA health care provider practices. You should register with the MIIS at the following website: www.miisresourcecenter.com. Registration with the MIIS also requires an onboarding process to ensure capacity to complete the required reporting and place vaccine orders directly through the MIIS. In order to receive COVID-19 vaccine, your site should:

  • Confirm that your facility is fully registered and on-boarded to submit vaccine-administered data to the Massachusetts Immunization Information System (MIIS): miishelpdesk@mass.gov
  • Confirm that your facility has signed and electronically submitted the Massachusetts COVID-19 Program (MCVP) Enrollment Form: DPH Vaccine Unit, dph-vaccine-management@massmail.state.ma.us

How can my facility confirm that we are listed as a vaccine provider with DPH and are able to receive vaccine once it is available?

Confirm that your facility is fully registered and on-boarded to submit data about administered vaccine to the MIIS by contacting the MIIS team MIIShelpdesk@state.ma.us. Confirm that your facility has signed and electronically submitted the Massachusetts COVID-19 Provider (MCVP) Enrollment Form in the MIIS by contacting the DPH Vaccine Unit at dph-vaccine-management@massmail.state.ma.us.

If a hospital has an urgent care center, should each site enroll separately or just the hospital?

All individual locations will need to enroll separately but sites will be receiving invitations directly as MCVP enrollment rolls out to additional provider locations.

Feedback